Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsAndrew witty

    Andrew Witty

    Jump to

    • GlaxoSmithKline picks insider Emma Walmsley as new CEO

      Walmsley, who joined Britain's biggest drugmaker in 2010 from L‘Oreal, will replace Andrew Witty who had previously announced his decision to retire on March 31, 2017.

    • Stop trying to defend huge price hikes: GSK CEO to drugmakers

      Drug prices have come under scrutiny in recent months after Mylan received public backlash for the sharp price increases the Epipen, an injection device to treat fatal anaphylactic shocks from food allergies or insect bites. The price of a two-pack Epipen has risen to nearly USD 600, from just USD 100 in 2007.

    • Drugs giant GSK says boss to step down next year

      British drugmaker GlaxoSmithKline said today that chief executive Andrew Witty will retire in 2017 after almost 10 years at the helm.

    • GlaxoSmithKline CEO Andrew Witty to bow out in March 2017

      Witty, a 31-year company veteran, has been under fire from some investors in the past three years as sales and profits have flagged. His reputation was further tarnished by a damaging bribery scandal in China.

    • Drugmaker GSK sees earnings growth returning in 2016

      Second-quarter net income fell to 149 million pounds from 654 million pounds a year earlier, while sales rose 6 percent to 5.89 billion pounds.

    • World's first malaria vaccine gets nod from EU regulators

      The world's first malaria vaccine got a green light on Friday from European drugs regulators who recommended it should be licensed for use in babies in Africa at risk of the mosquito-borne disease.

    • GSK to stop paying doctors to promote drugs: NY Times

      The company's decision comes at a time when GSK faces allegations of illegal payments to Chinese doctors and officials.

    • GSK boss to address China scandal at results

      CEO Andrew Witty is likely to give his perspective on what appears to have gone on and how it can be put right. Chinese authorities are investigating GSK deals with travel agencies worth up to 3 billion yuan ($489 million) that they allege were used to facilitate bribes.

    • I am a strong fan of India, says Sanofi-Aventis' CEO

      The past few years has seen several multi national pharmaceutical companies come to India looking to make acquisitions. One such company is Sanofi-Aventis who's chief executive officer Chris Viehbacher believes 'India is one of the most exciting countries in the world at this stage.'

    • GSK eyes acquisitions worth $2bn in India

      Global pharma giant GlaxoSmithKline is eyeing acquisitions worth USD 2 billion in India, the world's fastest-growing drug market, media reports said.

    • GSK's Andrew Witty not a fan of universal drug pricing

      He has the reputation of being perhaps the most outspoken CEO among the big pharma companies.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347